Amgen narrows neuro focus to inflammation

Despite early success for Amgen’s first marketed neurology product, the company will exit research and early development for neuroscience, narrowing its focus to neuroinflammation.

“To compete effectively, we need to make investments in the areas and platforms that will position us for long-term success,” David Reese, EVP of R&D at Amgen Inc. (NASDAQ:AMGN), said on the company’s 3Q19 earnings call Tuesday. “Through careful evaluation of our pipeline and the challenges inherent in developing drugs for major neurologic diseases, we have made the decision to end our neuroscience research and early development programs.” ...